Corporate Philosophy Otsuka-people creating new products for better health worldwide
|
|
|
- のぶのすけ とどろき
- 9 years ago
- Views:
Transcription
1 ANNUAL REPORT 2013
2 Corporate Philosophy Otsuka-people creating new products for better health worldwide
3 Contents
4 Group Structure ur & Overview vi of Main Operating Companies Otsuka-people creating new products for better health worldwide 02
5 Message sa e from the President Otsuka-people creating new products for better health worldwide 03
6 Worldwide Network Group Companies Otsuka-people creating new products for better health worldwide up Companies Group Compan 04
7
8 Business s Segments Otsuka-people creating new products for better health worldwide 4 Segments 8,509 2,518 06
9 26 Countries & regions 1,218.1 Billion yen 469 1,117 07
10 History of the Otsuka Group Otsuka-people creating new products for better health worldwide ~ ~
11 ~
12 The Otsuka Group s Business s Model Otsuka-people creating new products for better health worldwide 10
13 11
14 Financial n al Highlights g Otsuka-people creating new products for better health worldwide ,947 1,084,292 1,127,589 1,154,574 1,218,055 $12,951 91,520 98, , , ,660 1,804 47,084 67,443 82,370 92, ,429 1,302 2, ,438 62,456 44,793 43,302 63, ,296 46,626 48,097 48,062 45, , , , , ,364 2,045 1,298,790 1,458,376 1,589,717 1,666,767 1,779,208 18, , ,457 1,163,326 1,222,765 1,325,071 14, % 7.7% 7.9% 7.8% 9.7% 9.7% 62.3% 64.2% 72.4% 72.5% 73.7% 73.7% 23,518, ,156, ,835, ,835, ,835, ,835,617 22,928 24,589 25,188 24,595 25,330 25,330 1,200,000 1,000, , , , ,000 1,218,055 1,127,589 1,154,574 1,084, , , ,000 98,481 91,520 80, , , , , , , , , , , , , ,000 40, , % 20.2% 57.6% 20.3% 3.7% 6.2% 69.8% 12.9% 45.7% 41.4% % 14.5% 48.9% 12
15 Business s Segments Otsuka-people creating new products for better health worldwide 751, , , , , , , , ,853 18,421 22,144 21, ,914 49,207 46, , , ,664 2,177 2,309 2,446 4,372 1,943 3,
16 Progress Review of the First Medium-Term Management Plan Otsuka-people creating new products for better health worldwide % 7.1% 8.7% 8.5%
17 12,181 13,700 1, % 13,300 1,697 2, % 2,000 1,224 1, % 1,300 1,924 2, % 2,
18 Otsuka-people creating new products for better health worldwide 16
19 17
20 Otsuka-people creating new products for better health worldwide
21 TOPICS 19
22 Otsuka-people creating new products for better health worldwide TAS-102 FTY TPI TAS-102 F3dThd(FTD)+TPI F 3 dthd(ftd) F 3 dtmp F 3 dtdp F 3 dttp 20
23 TAS FU O HN O N H F DPD dutpase TAS-114 TOPICS 21
24 Pharmaceutical ca Segment Otsuka-people creating new products for better health worldwide 22
25 23
26 24
27 Pharmaceutical Segment 25
28 Phase I Phase II Phase III Phase I Phase II Phase III Phase I / II Phase I / II 26
29 Pharmaceutical Segment Phase I Phase II Phase III Phase II - III ** Phase I Phase II Phase III Phase I / II Phase IIb / III Phase I Phase II Phase III 27
30 研究開発活動 グローバルR&D拠点 UK GERMANY KOREA CHINA JAPAN SINGAPORE 大 製薬 徳島研究所 第十研究所 28 大 上海 薬物研究開発有限公司
31 Pharmaceutical Segment 大 製薬 徳島研究所 ハイゼットタワー 医療関連事業 大鵬薬品 つくば研究センター 大 製薬 大 製薬工場 大鵬薬品 基礎研究部門 臨床研究部門 徳島 U.S.A. JAPAN 探索第一研究所 探索第三研究所 微生物研究所 有機化学研究所 徳島研究所 製剤研究所 Qs 研究所 基盤技術研究所 診断事業部研究部 研究開発センター 技術センター 徳島研究センター 滋賀 兵庫 埼玉 茨城 藤井記念研究所 赤穂研究所 合成技術研究所 つくば研究センター 東京 診断事業部開発部 研究開発センター開発部 開発本部 大阪 新薬開発本部 U.S.A. UK GERMANY CHINA KOREA 大 メリーランドメディシナルラボラトリーズ Inc. 米国事業開発部アメリカ事務所 大 ファーマシューティカルD&C Inc. 大鵬ファーマUSA Inc. 大 ヨーロッパD&C Ltd. 大 フランクフルト リサーチインスティチュート GmbH 大 ノーベルプロダクツ GmbH 大 上海 薬物研究開発有限公司 大 製薬研発 北京 有限公司 大鵬薬品信息諮詢 北京 有限公司 韓国大 製薬 株 SINGAPORE 大鵬ファーマ シンガポール Pte Ltd. 大 製薬 藤井記念研究所 大 メリーランドメディシナルラボラトリーズ Inc. 29
32 Nutraceutical cal Segment Otsuka-people creating new products for better health worldwide 30
33 31
34 51% 50% 32
35 Nutraceutical Segment 26% 27% 62% 60% 58% 24% 33
36 34
37 Nutraceutical Segment 35
38 Consumer Products Segment Otsuka-people creating new products for better health worldwide Other Segment Otsuka-people creating new products for better health worldwide 36
39 TOPICS 37
40 Global Operations Otsuka-people creating new products for better health worldwide Americas 38
41 Europe 39
42 Global Operations Asia and Middle East 40
43 Corporate Governance Otsuka-people creating new products for better health worldwide 41
44 42
45 Corporate Governance 43
46 Social Responsibility Otsuka-people creating new products for better health worldwide 44
47 45
48 46
49 Social Responsibility 47
50 0 200, , , ,000 1,000,000 1,200, ,127, ,154, ,218, ,000 80, , , , , , , ,000 60,000 90, , ,000 82, , , ,000 80, , , , , , , Financial Review Otsuka-people creating new products for better health worldwide al Review Financial R ie 48
51 ,000 1,000,000 1,500,000 2,000,000 1,589, ,666,767 1,163,326 1,222, ,779,208 1,325,
52 -150, , , , ,000-50, , , , ,619 87,747-43,762 39,990 28, , ,509-41, ,340-91, ,889 50
53 Financial Review 51
54 52
55 Financial Review 53
56 Consolidated Balance Sheet Otsuka-people creating new products for better health worldwide , ,194 $ 3,695, , ,570 1,829,601 32,504 36, ,603 9,464 12, , , ,325 3,258,107 2,927 3,445 31,122 14,663 15, ,906 (543) (390) (5,774) 132, ,367 1,407,251 40,837 34, ,205 22,369 15, ,844 1,080,643 1,012,299 11,490,090 76,497 74, , , ,169 3,122, , ,583 3,204,881 75,073 72, ,224 16,858 17, ,245 26,487 11, , , ,946 8,399,777 (514,032) (488,431) (5,465,518) 275, ,515 2,934, , ,351 1,262, , ,614 2,001,733 37,788 36, ,786 36,062 30, ,434 26,467 25, ,414 15,236 16, , , ,953 4,493,333 1,779,208 1,666,767 $ 18,917,682 54
57 ,046 34,668 $ 415,162 15,484 7, ,636 8,849 8,524 94,088 86,985 84, ,880 6,284 6,690 66,816 3,444 3,259 36,619 63,731 42, ,629 33,515 33, ,353 58,076 50, ,501 1,929 2,186 20,510 29,129 36, , , ,359 3,683,913 12,332 31, ,122 40,571 44, ,377 3,108 3,091 33,046 24,005 26, ,237 13,389 15, ,360 11,258 7, ,702 3,002 3,403 31, , ,643 1,144,763 81,691 81, , , ,639 5,427, ,134 1, , ,411 8,169,219 (18,392) (8) (195,556) 8, , (39,824) (59,905) (423,434) (31,540) (59,144) (335,353) 14,469 13, ,844 1,325,071 1,222,765 14,089,006 1,779,208 1,666,767 $ 18,917,682 55
58 Consolidated Statement of Income Otsuka-people creating new products for better health worldwide ,218,055 1,154,574 $ 12,951, , ,263 4,187, , ,311 8,763, , ,649 6,959, , ,662 1,803,934 2,876 2,803 30,579 (1,211) (1,702) (12,876) 6,204 (2,712) 65,965 2,464 2,465 26,199 3,140 1,216 33,386 (2,571) (2,685) (27,337) (4,408) (3,665) (46,869) 322 (267) 580 (684) (2,186) ,348 7,279 (6,257) 77, , ,405 1,881,329 61,990 54, ,117 (8,206) (5,397) (87,251) 53,784 49, , ,155 92,813 1,309, , ,429 92,174 $ 1,301, $ Consolidated Statement of Comprehensive Income Otsuka-people creating new products for better health worldwide ,155 92,813 $ 1,309,463 7, ,733 (11) 15 (117) 12,000 (4,891) 127,592 9,000 (3,024) 95,694 28,582 (7,600) 303, ,737 85,213 $ 1,613, ,034 85,141 $ 1,595,258 1, ,107 56
59 Consolidated Statement of Changes in Equity Otsuka-people creating new products for better health worldwide 557,834 81, , ,967 (4) 359 (4) (52,446) 1,150,667 12,659 1,163,326 (26,776) (26,776) (26,776) 92,174 92,174 92,174 (2) (4) (4) (4) (7,459) (6,384) 383 (6,001) 557,832 81, ,639 1, ,411 (8) (59,905) 1,209,723 13,042 1,222,765 (29,334) (29,334) (29,334) 122, , , (216) 1,618 1,402 1,402 (8,258) (20,002) (20,002) (20,002) (191) (191) (191) (1,029) 7,534 (11) 20,081 26,575 1,427 28, ,242 81, , ,315 (18,392) 8,284 (39,824) 1,310,602 14,469 1,325,071 $ 868,591 $ 5,429,442 $ 12,057 $ 7,181,404 $ (85) $ 7,974 $ 117 $ (636,948) $ 12,862,552 $ 138,671 $ 13,001,223 (311,898) (311,898) (311,898) 1,301,744 1,301,744 1,301,744 (2,297) 17,203 14,906 14,906 (212,674) (212,674) (212,674) (2,031) (2,031) (2,031) (10,941) 80,107 (117) 213, ,563 15, ,736 $ 868,591 $ 5,427,145 $ 1,116 $ 8,169,219 $ (195,556) $ 88,081 $ $ (423,434) $ 13,935,162 $ 153,844 $ 14,089,006 57
60 Consolidated Statement of Cash Flows Otsuka-people creating new products for better health worldwide , ,405 $ 1,881,329 (66,829) (34,422) (710,569) 45,463 48, ,392 (2,464) (2,465) (26,199) (3,140) (1,216) (33,386) 2, ,571 2,685 27,337 4,408 3,665 46,869 (47,240) (25,658) (502,286) (5,516) (7,412) (58,650) (3,869) 8,473 (41,138) (1,864) (7,322) (19,819) 20,881 17, , , ,619 1,268,900 4 (6,954) ,392 (50,541) (36,034) (537,384) 16,166 17, ,887 1,382 (1,278) (11,232) (21,060) (119,426) (8,750) (10,655) (93,036) (1,539) (16,364) (29,091) (47,504) (309,314) (6,565) (3,642) (69,803) (91,229) (107,629) (970,005) 1,095 3,194 11,643 3,394 2,295 36,087 (16,121) (23,834) (171,409) (20,002) (4) (212,674) 248 2,637 (29,334) (26,776) (311,898) (454) (404) (4,827) (10,715) 4,464 (113,929) (71,889) (41,065) (764,370) 6,223 (1,362) 66,166 (37,555) (2,437) (399,309) 932 (695) 9, , ,326 4,084, , ,194 $ 3,695,598 58
61 Notes to Consolidated Financial Statements Otsuka-people creating new products for better health worldwide 59
62 60
63 Notes to Consolidated Financial Statements 61
64 62
65 Notes to Consolidated Financial Statements 39,878 14,870 1,578 53,170 83, ,916 39,721 8,436 5,438 42,719 90, ,072 $ 424,009 $ 158,107 $ 16,778 $ 565, ,889 5, , , ,570 $ 1,616,948 20, , , ,570 $ 1,829, ,504 36,596 $ 345, ,504 36,597 $ 345,603 53,170 42,719 $ 565,338 51,002 54, ,286 14,610 11, , , ,351 $ 1,262,967 $ 223 $ 43 $ $ 223 $ 43 $ 63
66 ,243 60,778 $ 757,501 25,842 26, ,769 35,267 31, , , ,367 $ 1,407, $ 8, , ,030 1, $ 12, $ , $ 10, $ 1, $ 2, $ 2, $ 2, $ 6,688 18,367 30, , , ,412 8,536 89,442 27,816 39, ,758 12,744 5, , ,595 2,590 2,974 27,539 12,332 31,735 $ 131,122 15,484 $ 164,636 3,571 37,969 3,789 40,287 2,522 26, ,433 1,939 20,617 27,816 $ 295, $ $ 755 1,325 $ 14, ,113 2,466 26,220 3,727 39,628 8,281 $ 88,049 64
67 Notes to Consolidated Financial Statements , ,331 $ 2,066,241 (171,107) (139,429) (1,819,320) 14,802 2, ,384 2,485 (15,071) 26,423 (15) (159) ,571 44,709 $ 431, ,633 7,571 $ 81,159 4,187 4,210 44,519 (3,829) (3,678) (40,712) (1,218) (596) (12,951) 4,846 4,905 51, ,625 12, , ,923 2,408 2,140 25,603 14,402 15,088 $ 153, %-6.00% 2.00%-7.00% 2.00%-8.00% 2.50%-9.00%
68 490,000 32, , , ,000 32, , , ,000 32, , , ,000 4, , ,435 40,000 50,000 27, , , ,100 ($0) ($22) ($0) ($22) 2,442 2,442 2,442 2,442 ($26) ($26) ($26) ($26) 2, ,099 0 ($22) ($0) ($22) ($0) 1 ($0) 2,100 ($22) 1 ($0) 2,100 ($22) ,577 15,147 $ 144,359 18,946 15, ,446 10,685 10, ,610 3,368 3,132 35,811 15,958 14, ,676 14,992 6, ,405 7,792 6,013 82,850 3,334 2,446 35,449 9,929 11, ,572 8,559 9,787 91,004 (30,132) (28,231) (320,383) 77,008 66, ,799 4, ,655 6,152 6,128 65,412 3,656 3,432 38,873 6,692 4,834 71,154 21,076 15, ,094 55,932 51,580 $ 594, % 40.6% (10.1) (12.1) (0.3) (0.1) (0.3) (0.0) 0.8 (2.0) 30.4% 34.8% 5,465 $ 58,107 4,281 45,518 7,201 76,566 4,394 46,720 31, ,587 52,997 $ 563,498 66
69 Notes to Consolidated Financial Statements , ,380 $ 1,660, ,691 99,842 1,102,509 14,465 14, ,801 4,848 4,667 51, , ,230 2,045, , ,823 1,945, , ,649 $ 6,959, $ 1, , , , , , , , , , ,031 3,198 $ 34,003 10, ,496 13,308 $ 141, $ $
70 347, , , , , , , , ,805 89,625 58,820 1,020,062 1,079,292 59,230 39,046 39, , ,293 33,515 33,515 18,996 19, , , , , , , , , , , ,625 70,829 43, ,579 1,011,237 43,658 34,668 34, , ,322 33,823 33,823 30,972 30, , ,
71 Notes to Consolidated Financial Statements $ 3,695,598 $ 3,695,598 $ 1,829,601 1,829,601 3,539,988 3,539,988 1,453,227 1,457,586 4, , , ,412 $ 10,845,953 $ 11,475,724 $ 629,771 $ 415,162 $ 415,162 $ 1,800,032 1,800, , , , , $ 2,773,525 $ 2,773,812 $ , , , ,500 48,500 1,500 1, ,097 49,027 1,500 1,000 $ 3,695,598 $ $ $ 1,829,601 3,540,159 5, , ,683 15,949 10,633 $ 9,410,919 $ 521,286 $ 15,949 $ 10, , ,989 $ 1,674,194 14,610 11, ,343 69
72 646 (1) (1) 556 (3) (3) 20 1,222 (4) (4) 482 (2) (2) 1,945 (3) (3) 13 2,663 (531) (531) 5,103 (536) (536) $ 6,869 $ $ (11) $ (11) 5,912 (32) (32) 212 $ 12,993 $ $ (43) $ (43) 1,800 1,800 (18) , (14) $ 19,139 $ 19,139 $ (191) 712 $ 7, ,467 2,850 30,303 70
73 Notes to Consolidated Financial Statements ,988 $ 116, ,563 11, ,394 (3,542) 200 (37,661) 7, $ 80,733 (2) (4) $ (21) (14) 25 (149) (16) 21 (170) 5 (6) 53 (11) 15 $ (117) 12,000 (4,999) $ 127, ,000 (4,891) 127,592 12,000 (4,891) $ 127,592 8,969 (2,977) $ 95, (47) 330 9,000 (3,024) $ 95,694 28,582 (7,600) $ 303,902 (389) $ (4,136) (870) (9,250) (919) (9,771) 298 3, (1,869) (19,872) 148 1, ,934 (1,539) (16,364) (1,539) $ (16,364) (1,278) (1,278) (1,278) (1,278) 217 1,849 2,066 (684) 1,382 1, , , $ 2.36 (152) , , $ , , (173) , ,
74 16,507 $175, , ,929 45,237 75,027 1,218,055 1,218,055 4,844 1,652 36,637 43,133 (43,133) 850, ,773 46, ,664 1,261,188 (43,133) 1,218, ,853 21,367 (2,446) 3, ,693 (41,033) 169, , , , ,191 1,055, ,800 1,779,208 18,995 10,222 1,756 4,494 35,467 5,148 40,615 2,807 1, ,848 4,848 21,457 10, ,964 10, , ,456 37,951 14,939 2,735 3,973 59,598 3,658 63,256 72
75 Notes to Consolidated Financial Statements 782, ,282 47,990 73,054 1,154,574 1,154,574 3,543 1,217 35,549 40,309 (40,309) 782, ,825 49, ,603 1,194,883 (40,309) 1,154, ,481 22,144 (2,309) 1, ,259 (41,597) 148, , , , , , ,176 1,666,767 19,939 11,276 1,954 4,946 38,115 5,280 43,395 2,749 1, ,667 4,667 17,543 8, ,762 10, , ,657 20,811 11,502 1,970 4,556 38,839 4,463 43,302 $ 9,046,911 $ 2,625,508 $ 480,989 $ 797,735 $ 12,951,143 $ $ 12,951,143 51,505 17, , ,618 (458,618) 9,046,911 2,677, ,554 1,187,283 13,409,761 (458,618) 12,951,143 1,997, ,187 (26,007) 41,669 2,240,223 (436,289) 1,803,934 6,271,781 2,208,177 1,421,340 1,320,478 11,221,776 7,695,906 18,917, , ,687 18,671 47, ,108 54, ,845 29,846 19, ,350 51,547 51, , ,613 1,116, ,045 1,567,847 1,567, , ,841 29,080 42, ,684 38, , , ,541 1,218, , ,009 1,154,574 $4,662,562 $8,288,581 $12,951,143 73
76 595, , ,069 1,218, ,888 64, , , , ,196 1,154, ,443 49, ,515 $ 6,329,697 $ 4,738,735 $ 1,882,711 $ 12,951,143 $ 2,252,929 $ 681,330 $ 2,934, , , , ,590 $1,421,510 1,370,877 1, , ,685 $12,025 $10,144 $2,275 $2,138 $755 $27,337 74
77 Notes to Consolidated Financial Statements 2,807 1, ,848 7,102 28, ,063 37,788 2,749 1, ,667 5,166 28, ,190 36,825 $29,846 $19,681 $ 670 $1,350 $ $51,547 75, ,618 5,720 21, ,786 2, ,464 21,663 2,342 24,005 2, ,465 23,871 2,598 26,469 $23,477 $ $ $ 2,722 $ $26, ,335 24, ,237 75
78 Independent nt Auditors' Report Otsuka-people creating new products for better health worldwide 76
79 77
80 Corporate Information Otsuka-people creating new products for better health worldwide 78
81 Shareholder er Information Otsuka-people creating new products for better health worldwide 64, , , , , , , , , , % % % % 32, % % 5, % 3, % % 40, % % % % 79
82
Otsuka-people creating new products for better health worldwide Contents 02 03 07 08 11 13 15 16 17 01
3 Otsuka-people creating new products for better health worldwide Otsuka-people creating new products for better health worldwide Contents 02 03 07 08 11 13 15 16 17 01 To Our Shareholders Otsuka-people
Contents FY2011 Highlight Financial Data Business Outline Of ZOZOTOWN To Overseas Customers Business Outline Of Affiliated Companies About Us Appendix : Notice of the 14th Annual General Meeting of
Annual 2002 Report Financial Highlights 2002 2001 2000 2002 2,581,399 2,750,418 2,680,611 19,372 28,402 26,494 11,173 213 4.17 3.89 1.64 $ 0.031 907,150 979,695 889,220 6,807 4,030,596 4,232,011 4,172,459
株式会社幸楽苑
35th Business Report http://www.kourakuen.co.jp/ To Our Shareholders Management Report CONTENTS 1 2 3 6 7 8 9 11 14 15 16 17 1 2 Management Strategy 3 4 5 6 Management Strategy Commentary Information 7
Q A Q A 1
IHI Report Q A Q A 1 Q A Q A To Our Shareholders 2 706 803 42 9 1,030 790 66 17 1,894 1,716 55 103 3 Business Review by Segment 1,350 57 45 1,310 704 34 16 755 103 31 16 41 763 16 10 554 4 Performance
ozu_no98_H.qxd (Page h1)
To Our Shareholders CONTENTS 1 2 3 4 56 78 911 112 13 14 TM 1 2 Group Corporate Information Segment Information 3 4 Topics Topics1 Topics2 Topics3 5 6 8 Special Contents 7 Financial Statements [Consolidated]
maiji2007_cover_j_0907
27 CORPORATE PHILOSOPHY THE MEIJI DAIRIES GROUP CONTRIBUTES TO A HEALTHY AND HAPPY DAILY LIFE FOR OUR CUSTOMERS BY OFFERING NEW LEVELS OF VALUE IN FOOD. CONTENTS 2 4 6 1 1 11 12 13 14 16 18 19 2 22 23
株式会社フジテレビジョン
67 194119930 Cover 2 Top Message 3 Top Interview 6 Topics 7 Fuji TV Outline 11 Consolidated Financial Statements 13 Non-Consolidated Financial Statements 14 Corporate Social Responsibility Report 15 Group/Network
ゼリア新薬工業株式会社
C O N T E N T S TOP INTERVIEW Q A Q A Q A 10.9 22.9 66.2 ZERIA Pharmaceutical Co.,Ltd. 1 TOP INTERVIEW Q A 2 ZERIA Pharmaceutical Co.,Ltd. ZERIA Pharmaceutical Co.,Ltd. 3 Q A Q A Q A Q A R&D III II I II
9104
01 To Our Shareholders 02 03 Consolidated Financial Statements 12,000 8,878 9,039 9,102 9,972 11,300 8,000 5,636 4,000 0 2001/3 2002/3 2003/3 2004/3 2004/9 2,000 1,500 1,600 1,000 500 530 373 334 905 742
株式会社ハローズ
Contents 1 2 3 5 7 9 Financial Highlights Message From The Management Q A A Toshiyuki Sato Q Top Interview Q A Q Q A A Top Interview Shop Close Up Ibara Shop Close Up Financial Statements Financial Statements
NEC THE INTERNET SOLUTION PROVIDER NEC NEC 12 NEC 16 NEC NEC NEC NEC NEC NEC
NEC CORPORATION NEC NETWORKS NEC SOLUTIONS THE RIGHT STRENGTHS FOR THE INTERNET ERA NEC ELECTRON DEVICES NEC THE INTERNET SOLUTION PROVIDER NEC 1 2 6 10 NEC 12 NEC 16 NEC 20 24 54 55 56 NEC NEC NEC NEC
FINANCIAL FACT BOOK 2002 CONTENTS CONTENTS Sales Data Net Sales Sales Composition Sales by Region Profit Data Cost Composition & Operating Income/Net
FINANCIAL FACT BOOK 2002 FINANCIAL FACT BOOK 2002 CONTENTS CONTENTS Sales Data Net Sales Sales Composition Sales by Region Profit Data Cost Composition & Operating Income/Net Sales Gross Profit Margin
*1和-1 共通(HD-ミライト) ホールディングス会社概要
Corporate Profile Corporate Slogan President s Message Corporate Philosophy Promise Solutions Engineering Support ICT Solutions Social Innovation Mobile Network Communications Infrastructure Environmental
191590-21 -21 20051 2 Industrial automation and control business PAGE 16 Test and measurement business PAGE 18 New and other businesses PAGE 20 Conten
New action strategies for growth 191590-21 -21 20051 2 Industrial automation and control business PAGE 16 Test and measurement business PAGE 18 New and other businesses PAGE 20 Contents YOKOGAWA Enterprise
CONTENTS
Annual Report 2017 CONTENTS Santen Pharmaceutical Co., Ltd. Annual Report 2017 1 Value Creation 2 Santen Pharmaceutical Co., Ltd. Annual Report 2017 Santen Pharmaceutical Co., Ltd. Annual Report 2017 3
YUHO
-1- -2- -3- -4- -5- -6- -7- -8- -9- -10- -11- -12- -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- -24- -25- -26- -27- -28- -29- -30- -31- -32- -33- -34- -35- -36- -37- -38- -39- -40- -41- -42-
untitled
1 Report 3 4 8 10 14 16 Topics 18 18 19 19 20 20 21 21 22 23 Information 25 25 2013.9 No.80 1 2 2013.9 No.80 Report 2013.9 No.80 3 4 2013.9 No.80 2013.9 No.80 5 6 2013.9 No.80 2013.9 No.80 7 8 2013.9 No.80
At TOKYO GAS CO., LTD. Annual Report 2001 For the year ended March 31, 2001 The Frontier Of Change 2001 2000 1999 2001.......................................... 1,086,771 992,255 997,767 $ 8,835,537........................................
アニュアルレポート２００３
..................................... 1............................. 2 6 8 10 12 14............................ 16..................... 20.............................. 21.........................................
2014CSR.pdf
Performance Through Chemistry Corporate Social Responsibility Report CSR REPORT 2014 Responsible Care OUR COMMITMENT TO SUSTAINABILITY Contents 1 2 Responsible Care OUR COMMITMENT TO SUSTAINABILITY Top
Top Interview 倉 社 長 に 聞 く 一 問 一 答 Q Q2 Q3 7,3242.8% % % Love Mary Love MaryAKB48 Q4 10 Q5 Q ,350 1,420 倉 正 治 1,100
91831 11 831 2 41 41 168-0063 84 0120-782-031 第 36 期 中 間 報 告 書 I R R E P O RT 2011 年 9 月 1 日 2012 年 2 月 29 日 URLhttp://www.kuraudia.co.jp/ TEL 0753152345 FAX 0753113607 E URLhttp://www.kuraudia.co.jp/inquiry/index.html
* ,195,393 1,269,415 $8,987,917 45,664 96, ,338 10,679 50,318 80,293 5,180 25,177 38,947 ** 1,193,011 1,240,008 8,970,008
2002 2002 3 Breakthrough * 3 31 1 2002 2001 2002 1,195,393 1,269,415 $8,987,917 45,664 96,024 343,338 10,679 50,318 80,293 5,180 25,177 38,947 ** 1,193,011 1,240,008 8,970,008 ** 496,826 516,013 3,735,534
業績報告｜ディスクロージャー│チューリッヒ｜Business Report 2008 会社概要編
V ision Statement Contents 03 04 06 08 09 10 12 13 16 19 20 23 Greeting from Our CEO - Makoto Ozeki Zurich Insurance Company, Japan Branch Profile Zurich Financial Services Group Profile Financial Highlights
???
LOTTE PROFILE 2013 PREPARED WAY contents PREPARED WAY LOTTE 3 Global Strategy 4 Message from the Chairman 6 Vision 2018 10 Global Passion 11 Social Responsibility 18 Financial Information 21 PREPARED WORLD
